Armor Dental, a privately held dental manufacturer and developer of Mouth-Mate® and Scan-Mate®, is pleased to announce a North American strategic distribution partnership with Neoss, a leading global implant company whose mission is to advance the science of dental implant treatment for all patients. Starting this month, Neoss will distribute Mouth-Mate, the first implant hygiene device for home care and Scan-Mate, the first non-reflective retraction instrument for intraoral scanning and surgical procedures performed chair side.

“Our partnership with Armor Dental makes perfect sense for Neoss as it strengthens our unwavering commitment to our customers’ most important goal, which is their patients’ implant success for a lifetime,” said Mark Neri, President, Americas, Neoss, Inc. This is more than a distributor agreement, it represents a collaborative partnership as we are now extending care from the office and connecting our customers into their patients’ homes for the first time. We couldn’t be more excited to include Armor Dental’s innovative products – Mouth-Mate for improving implant hygiene and Scan-Mate, a new retraction technique and device for our digital portfolio.”

Mouth-Mate:

Neoss customers will differentiate their practices by providing a new in-home hygiene device to help their patients improve daily implant care.

First retraction tool for fixed cases to visibility, access, and focus under the prosthesis.

New two-handle brushing and retraction approach for implant hygiene that will improve long-term implant success.

Bridge hygiene protocol from specialty office to restorative office.

Create a more meaningful support connection between the dental office to the patient at home.

Scan-Mate:

Non-reflective and autoclavable retraction instrument for intraoral scanning and all dental procedures.

Improve digital work flow and first impression in the chair.

Fully autoclavable instrument up to 60 cycles that can be used for all operatories.

Improve intraoral scanning quality from single restoration to full-arch cases, crowns, bridges, implants and orthodontics.

Ideal retraction tool for flap surgeries that is gentle and protective of tissue.

Soft bendable handle and tip provides smooth retraction and easier access for hard to reach areas.

“Armor Dental is very excited to forge this partnership with Neoss as it represents the first time an implant company is taking a meaningful stand for implant hygiene at home for their customers,” said Cherie Le Penske, CEO of Armor Dental. “Neoss’ thoughtful approach to creating implant solutions that simplify complexity, improve case acceptance, and deliver greater value to help practices grow dovetails with our focus to improve patient care in the office and extend it further into the home than ever before.”

Dental professionals attending the Academy Of Osseointegration Annual Dental Meeting in Washington D.C. are invited to experience these products hands-on, and to learn more about many other innovative solutions, by visiting Neoss at Booth #723 at the Walter E. Washington Convention Center on March 14-16, 2019.

About Armor Dental Corporation

Armor Dental’s founding mission is to modernize patient recovery at home and improve digital work flow for the dental team. We have developed an entirely new category of patented dental products that aid in the healing of post-procedure hygiene to improve patient comfort and healing at home through our first product line, Mouth-Mate and recently introduced the first non-reflective retraction instrument, Scan-Mate. Our team is passionately committed to improving oral health by empowering patients and clinicians from the dental office to home with helpful products, clinical data, and superior customer service. Visit www.armor-dental.com.

About Neoss, Inc.

Neoss offers intelligent products that are intuitively simple to use. Our products allow dental professionals to provide reliable and cost-effective treatments to their patients with excellent long-term results. Leading the market with ingenuity and integrity, we strive to set new standards. In developing smart treatment solutions and working closely with each practice, Neoss makes the complex less complicated. We call that Intelligent Simplicity. Call 866-626-3677 or go to www.neoss.com for more info.

Sterngold Dental, LLC, and Merz Dental GmbH have announced that the Baltic Denture System (BDS) is now available to purchase through Sterngold Dental, LLC. The BDS product line and its processes open up a new way of fabricating full dentures in a digital workflow. Prosthetic processing steps for Sterngold’s Implant Systems, in particular the MOR® Mini Implant System, have been incorporated into the digital denture workflow.

Featured in the BDS is the ^BDLoad®, a milling blank in which the dental arches are integrated in a functional tooth setup. The arches come in the sizes of small, medium, and large, as well as in the jaw widths of narrow, medium, and wide. The ^BDLoad® is available in a variety of shades, has no shrinkage, is biocompatible, and is very strong and not prone to tooth fracturing. Since the teeth are already incorporated in the ^BDLoad®, missing or broken dentures can be reproduced faster when compared to other digital denture systems.

CEO of Merz Dental, Friedhelm Klingenburg says, “I am pleased to have Sterngold become a prime partner for our BDS system, to provide a perfect solution to dental practices, laboratories and, most importantly, to the patients. With Sterngold‘s expertise in implantology, the BDS will increase efficiency in the overall process for digital dentures.”

In as little as two clinical visits, a patient can have a new, accurate, and esthetically superior denture compared to the traditional way, which averages five visits. Labs will also be able to produce unparalleled results with increased efficiencies in time and labor. With the advent of the Baltic Denture System’s commitment to speed and maximum efficiency, a laboratory or clinical practice can begin overdenture cases today without any large start-up investments.

“With the partnership of Sterngold and Merz solidified, the digital Baltic Denture System and all of its components are now available through Sterngold. Along with our customer and technical support, we now offer the best digital denture option with the choice of bundling our versatile selection of Sterngold dental implants to fabricate cutting-edge overdenture prosthetic applications. The BDS system will provide positive customer and patient experiences, all while saving valuable lab and chairside time,” says Gordon Craig, President & CEO of Sterngold.

For more information, system details, and how-to videos please visit www.sterngold.com/denture-system.

Henry Schein, Inc. (Nasdaq: HSIC), through its Henry Schein One joint venture, today announced that it has acquired Lighthouse 360, a provider of easy-to-use dental practice management and patient communication software that complements Henry Schein One's strategy to deliver integrated technology platforms that help dental teams become more productive and improve each stage of the patient experience.

Founded in 2006, Lighthouse 360 was previously a part of Web.com and had 2018 sales of approximately $50 million. Henry Schein, Inc. expects that Lighthouse 360 will be neutral to the Company's 2019 earnings per diluted share and accretive thereafter. Financial terms were not disclosed.

Henry Schein One is a joint venture between Henry Schein, Inc. and Internet Brands that delivers integrated technology to enhance dental practice management. As the latest addition to Henry Schein One's portfolio, Lighthouse 360 furthers the Company's mission to tightly integrate best-of-breed solutions into one technology system to help dental practices run more efficiently.

"Lighthouse 360 is an innovative provider in the large and highly fragmented market for patient engagement software," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Lighthouse 360's highly automated software platform will expand our practice marketing and client communication solutions, providing tools to better connect us with our dental customers, and to help dental practitioners better connect to their patients."

Lighthouse 360 serves more than 11,000 dental practices with a wide range of web-based tools that automate tedious tasks and help practices save time, reduce no-shows, and build stronger relationships with patients. Lighthouse 360 software has been recognized with numerous industry awards and is highly rated by users, with 90 percent of surveyed Lighthouse 360 users reporting that the software has increased their practice's efficiency.

"As we explored this acquisition, it quickly became clear that Lighthouse 360's relentless focus on task automation, product innovation, and exemplary customer service made it a natural fit within the Henry Schein One portfolio," added James A. Harding, Jr., Chief Executive Officer of Henry Schein One. "Lighthouse 360 is in many ways a microcosm of Henry Schein One – a passionate group of technology innovators that put practice efficiency and patient experience at the forefront of everything we do."

The Lighthouse 360 brand will remain intact and will continue to offer and support all current products following the acquisition. The Company has nearly 150 employees and is headquartered in Sugar Hill, Georgia.

"Henry Schein One's dental expertise and deep technology resources make it the ideal partner for Lighthouse 360," said Sharon Rowlands, CEO and President of Web.com. "We are excited about the future of Lighthouse 360 knowing that it will be aligned with a dynamic organization focused on addressing the unique challenges faced by the dental industry."

About Lighthouse 360

Lighthouse 360 automates dentists' daily consumer interactions and office routines such as appointment reminders, leading to improved operational efficiency and business results. The award-winning software has helped customers increase production by an average of 30 percent, and its features designed to boost practice efficiency, on average, save dental practices 16 hours per week and eliminate seven hours of weekly phone time for the front desk. For more information about Lighthouse 360, visit www.lh360.com.

About Henry Schein One

Henry Schein One, founded in 2018, is the world's largest dental practice management software company. Headquartered in American Fork, Utah, the company includes Henry Schein's market-leading solutions of Dentrix, Dentrix Ascend, Dentrix Enterprise, Easy Dental, and TechCentral, as well as international companies, including Software of Excellence, Logiciel Julie, InfoMed, Exan, and LabNet, among others. Also included in Henry Schein One are the dental businesses of Internet Brands, including web-based solutions such as Demandforce, Sesame Communications, Officite, DentalPlans.com and more. The new company integrated more than 40 software brands and employs approximately 1,500 people. For more information, visit www.henryscheinone.com.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales from continuing operations reached $9.4 billion in 2018, and have grown at a compound annual rate of approximately 13% since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; new or unanticipated litigation developments; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence on third parties for certain technologically advanced components; increased competition by third party online commerce sites; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; and certain provisions in our governing documents that may discourage third-party acquisitions of us; changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

vhf has won this year’s iF Design Award and therefore joins a selective club of winners recognized by the world-renowned design label. The R5 dental milling machine won the award in the Industry/Tools category for its outstanding product design. The award is presented once a year by the world’s oldest independent design institution, iF International Forum Design GmbH in Hanover, Germany.

Combining intuitive technology with deliberate design: vhf camfacture AG impressed the independent and international jury of 67 experts with its milling and grinding machine. The uncompromising and confident design language of the highly automated dental machine underlines vhf’s claim to always be a step ahead of the times. This means that the R5 is an absolute optical highlight in addition to producing perfect restorations in a digital workflow.

Jürgen Schmid, Managing Director of the internationally successful company Design Tech, which designed the exterior of the R5, summarizes the appearance of the machine as follows: “The R5 is a high-quality, functional product with a sophisticated operating concept and a user-friendly user interface. vhf has more than earned the iF Award with its R5.” Regarding the development process, he says: “I experienced it myself: vhf outdid itself with the development of this innovation. It was an extraordinary achievement and I have great respect for their work.” The competition for the award was equally impressive: The jurors had to sift through 6,375 entries from 52 countries vying for the coveted award. The iF Award is presented in a total of seven categories.

Dr. Jens Butschan, head of the vhf division Innovation and Development, is delighted about this latest award for the company: “The R5 is a clear affirmation of the outstanding craftsmanship of high tech made in Germany. It reflects our consistent approach to producing modern and innovative technology in a user-friendly and high-quality design. We are thrilled to have received this great recognition!”

The iF Award was presented at a ceremony at the BMW World in Munich, Germany, on March 15.

IDS 2019 Highlight

BioHorizons Camlog is adding the innovative IntraSpin® System from Intra-Lock® to its comprehensive portfolio of regenerative biomaterials. The IntraSpin® System is designed to obtain autologous leukocyte platelet-rich fibrin (L-PRF®) fibrin matrices and ensures good material biocompatibility. It is manufactured in Germany and has both CE approval as a Class IIa medical device and FDA approval for the American market.

What is L-PRF®?

By means of the L-PRF® technique, certain constituents and signaling substances can be released from autologous blood, which are reintroduced into the wound area to promote natural wound and tissue healing. The therapy is 100% natural and additive-free. Natural growth factors present in the patient´s body are concentrated when using L-PRF®. Making use of this autohemotherapy, the patient´s own concentrated platelets and other key blood cells are simply re-introduced into the site of the surgical procedure. As a result, the body´s own constituents are used to release powerful healing proteins and create a scaffold for healing.

The combination of this minimally invasive procedure with the proven products from BioHorizons® biologics promotes and accelerates soft tissue and bone regeneration, as scientific studies clearly show. As Professor Nelson R. Pinto once put it: “L-PRF®, a human living tissue that challenges the paradigm of osseointegration and tissue regeneration. What we thought impossible yesterday, could be routine tomorrow with L-PRF®

and natural guided regeneration.”

Indications and clinical application

In the last few years, interest and research in this topic has piqued. Science has delivered a wealth of new information on the mechanisms underlying the growth-factor processes of osseointegration and tissue regeneration, and has investigated the most suitable therapy concepts in each situation. Supplemented and updated information on therapy concepts are in the latest issue of "Guidelines for the use of L-PRF®", written by experts in the field of L-PRF®, in order to facilitate compilation of the most effective therapy concepts.¹

Worldwide focus on science and education

BioHorizons Camlog is focusing on high-level education and a strong scientific basis for the application of L-PRF®. In 2019, the clinical master BioHorizons L-PRF® course in Italy with Prof. Testori – as well as CAMLOG’s and Rocker & Rocker GmbH courses in Hamburg, Frankfurt, Dusseldorf, Munich are great examples of BioHorizons Camlog continuous educational commitment. For worldwide distribution, BioHorizons Camlog will resort to its subsidiary and distributor network. In the German, Austrian and Swiss markets, distribution of the IntraSpin® System will be handled by Rocker & Rocker GmbH for Camlog. "Working together with Robin Rocker and his team, we have an ideal partner with many years of experience in the distribution of autologous blood products at our side," said Martin

Lugert, Managing Director of Camlog DACH. "I am delighted that the IntraSpin® system gives our customers access to the safe and fast reprocessing of autologous L-PRF® products".

As part of Henry Schein's Global Dental Surgical Group (GDSG), BioHorizons and Camlog work closely together to expand their combined global market position. The products of Intra-Lock®, also part of GDSG, complement the product range of BioHorizons and Camlog with innovative technologies such as the IntraSpin® System.

About BioHorizons and Camlog

BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. They are committed to developing evidence-based and scientifically proven products, as well as continuous education according to highest standards.

Headquartered in the U.S. and Europe, respectively, BioHorizons and CAMLOG’s geographic positions allow them to efficiently serve direct subsidiaries in the Americas and Western Europe, as well as their entire distribution network in more than 80 countries around the world. The companies are part of Henry Schein, Inc., a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. The Company’s Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. For more information, visit www.biohorizons.com, www.camlog.com and www.henryschein.com.

References

1. Nelson R. Pinto1, Andy Temmerman2, Ana B. Castro2, Simone Cortellini2, Wim Teughels2, & Marc Quirynen2 University of the Andes,

Department of Periodontics and Implant Dentistry, Faculty of Dentistry, Santiago, Chile and Catholic University of Leuven / University

Hospitals Leuven, Department of Oral Health Sciences, Periodontology, Leuven, Belgium. 

At IDS 2019, BioHorizons and Camlog present a variety of innovations for implant-based tooth replacement. The comprehensive lines of dental implants, restorative components, CAD/CAM and regenerative solutions are tailored to the diverse individual needs of today’s clinical challenges in daily practice.

Highlights at IDS 2019 include:

• The launch of a new implant line geared to high primary stability and modern treatment concepts– the PROGRESSIVE-LINE, available for the established CAMLOG® and CONELOG® connections;

• The presentation of an innovative line extensions to the BioHorizons Tapered Implant System introducing the Tapered Short implant and the Tapered Immediate Molar;

• The display of further developments of the CERALOG® 2-piece ceramic implant system increasing prosthetic ease-of-use;

• With Intra-Spin®, a centrifuge to create L-PRF®, a three-dimensional autologous combination of platelet rich fibrin derived from the patient's blood, BioHorizons and Camlog are complementing the comprehensive portfolio of regenerative solutions; and,

• BioHorizons and Camlog announced the CE certification of a novel acellular dermal matrix derived from porcine tissue, intended for soft tissue applications – NovoMatrix™ – designed for cellular repopulation and revascularization.

Todd Strong, Chief Technology Officer of BioHorizons Camlog comments: “We are convinced that our comprehensive, evidence-based, and scientifically proven portfolio of products offers ideal solutions for the individual preferences of today’s implantologists and specialists. Our approach of an open digital workflow ensures that our solutions can work with a number of preferred equipment and software available in the market today. By combining a diverse offering of surgical, prosthetic and restorative options from within our group, our customers benefit from a variety of options. These options are all complemented by high-class education and backed by high scientific standards.”

Joining forces, accelerating evolution.

Since 2016, BioHorizons and Camlog, the premium implant companies within Henry Schein’s Global Dental Surgical Group, have pursued an evolutionary pathway to combine their strengths and conquer a global leadership position together. At first, BioHorizons and Camlog unified their go-to-market approach in all subsidiary markets, using the complementary strength of each other – complementing the product portfolios and enabling increased service levels to their customers. In 2018, the international sales channels were combined, creating five regional sales organizations: APAC, Western Europe, DACH (GER/AUT/SUI), the Americas and Rest of World, thus, enabling local customer centricity in each market, and focus on the fast-growing international markets. During these years, a strong global team and culture was formed, mainly building on long-standing team members, with talent, and dental experience from within both companies.

“We always focus on our people - especially during transformation. Trust and loyalty within the organization are the basis. Building an inspiring and empowering culture is key to win in today’s fast changing environment,” said Dr. René Willi, President, Global Dental Surgical Group of Henry Schein. “BioHorizons Camlog is well positioned to continue winning market share in the global challenge. Yet, we have preserved our strength of being present locally, keeping strong relationships with our customers, and a high identification with our brands and values. The quality of our teams make the difference - keeping the family feeling, and the continuity while accelerating. Welcome to BioHorizons Camlog.”

The new combined group branding of BioHorizons Camlog marks a subsequent milestone of combining two industry leading companies to jointly grow on a global scale, while reinforcing the identity of the established brands. Camlog will continue to be the leading brand in the German speaking markets. BioHorizons will continue to lead in the Americas. We introduce the group branding with great care, building on our history in each market, and the high identification and loyalty of our customers and employees. The group brand symbolizes our joint DNA of creating individual, intelligent, and inspiring solutions. The group brand will be used to strengthen our joint global brand awareness, building on the strong brand equity of BioHorizons and Camlog,” said Holger Essig, Chief Marketing Officer.

Camlog Germany – a role model for continued success.

In 2019, Camlog is celebrating 20 years of continued success. A very important success factor is the teams` evolutionary spirit: that evolution only works with each other, that evolution is based on cooperation and strong partnerships, that learning from others makes the difference, and lateral thinking leads to new horizons – transferring ideas and spirit into business, and helping customers grow their practice by offering value added services and education beyond implants. According to Camlog, that is why in the meantime, every fourth implant sold in Germany is from Camlog - a result of 20 years of continuity and creativity.

“We would like to thank all our customers for the valuable insights provided, helping us to develop and grow our solution portfolio, as for their loyalty and support. The IDS 2019 product launches, especially PROGRESSIVE-LINE and our innovative regenerative solutions, will be essential to satisfy the expanding needs of our customers, win new customer segments, and continue our growth path,” said Martin Lugert,

Managing Director of Sales, Camlog Germany.

Focus on science and education. BioHorizons and Camlog have always been focusing on a strong scientific base and high-level education. The Global Education Tour with its global event this year in Cartagena, Colombia, and further events in Italy, Japan, Spain, and Chile or the 6th Lab Technician Congress in Frankfurt are great examples of BioHorizons Camlog continuous educational commitment. Another highlight will be the ORAL RECONSTRUCTION FOUNDATION’s Global Symposium in New York, in April 2020.

About BioHorizons and Camlog

BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. They are committed to developing evidence-based and scientifically proven products, as well as continuous education according to highest standards.

Headquartered in the U.S. and Europe, respectively, BioHorizons and Camlog’s geographic positions allow them to efficiently serve direct subsidiaries in the Americas and Western Europe, as well as their entire distribution network in more than 80 countries around the world.

The companies are part of Henry Schein, Inc., a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. The Company’s Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. For more information, visit www.biohorizons.com, www.camlog.com, and www.henryschein.com.  

In close collaboration with practicing surgeons, Camlog developed a new implant line to meet the demands for shorter treatment times, earlier prosthetic restoration, and fewer sessions. Hundreds of CAMLOG® PROGRESSIVE-LINE implants have been placed during the last nine months right after the first presentation of this new implant line at the Global Symposium of the Oral Reconstruction Foundation in Rotterdam in April 2018. Since then, surgeons experienced an implant that reliably achieves excellent primary stability in all bone classes and proved the results of in-vitro tests to be

reproducible in the clinical routine.

Whereas current concepts in the market for immediacy are realized mainly by niche implants, suitable for specific situations or bone types only, PROGRESSIVE-LINE was developed to be an implant suitable for all indications. The outer geometry of the new implant line − available for both the renown CAMLOG® and CONELOG® connections − was geared to facilitate the implementation of treatment concepts like immediate placement and restoration and has been coupled with highly efficient protocols for the implant bed preparation in all bone types.

Well thought out features of this apically tapered implant prove to be particularly advantageous in soft bone. Threads down to the apex that make PROGRESSIVE-LINE ideal for immediate implantation, while also including a coronal anchorage thread helps to master complex situations in reduced bone height e.g. when performing sinus lift surgery. Additional features encompass a broadened thread height with strongly engaging threads, and flexible drill protocols which allow to adapt thestability according to the needs of the treatment plan. In addition, advanced drill designs offer efficient implant site preparation in dense bone − without requiring additional tools or a tap.

About BioHorizons and Camlog

BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. They are committed to developing evidence-based and scientifically proven products, as well as continuous education

according to highest standards.

Headquartered in the U.S. and Europe, respectively, BioHorizons and Camlog’s geographic positions allow them to efficiently serve direct subsidiaries in the Americas and Western Europe, as well as their entire distribution network in more than 80 countries around the world.

The companies are part of Henry Schein, Inc., a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. The Company’s Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

For more information, visit www.biohorizons.com, www.camlog.com and www.henryschein.com. 

Zest Dental Solutions, the only manufacturer of the LOCATOR® Family of Attachment Systems and provider of clinician trusted dental materials and small equipment, announces their second quarter roster of Continuing Education (CE) Courses.

Zest’s mission is to enhance the knowledge and skills of the clinician through unique education opportunities helping them provide the highest quality treatment to their patients. Classes are led by nationally recognized and accredited industry leaders at the Zest Corporate Headquarters in Carlsbad, CA and at other locations throughout the country. Attendees will receive applicable CE Hours upon completion of each course.

Courses for the second quarter of 2019 include:

To view a complete list of dates and course information, or to register for an upcoming course, visit https://www.zestdent.com/index.php/education or call 800-262-2310, ext. 344.

About Zest Dental Solutions

Zest Dental Solutions is a global leader in the design, development, manufacturing and distribution of diversified dental solutions for a continuum of patient care from the preservation of natural teeth to the treatment of total edentulism. The company's product offering consists of a range of solutions including the LOCATOR® Family of Attachment Systems, Consumables and Dental Equipment, with global distribution through Implant Companies, dealer/distributor networks, as well as a domestic retail sales operation. Zest Dental Solutions is headquartered in Carlsbad, California with operations in Anaheim and Escondido, California. Zest Dental Solutions is a portfolio company of BC Partners, a leading private equity firm. For more information, please visit www.zestdent.com.

Newswise — The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a grant to researchers at New York University College of Dentistry (NYU Dentistry) to study HIV latency. The grant which began February 1, provides nearly $2 million over five years to support research led by David N. Levy, PhD, associate professor of basic science and craniofacial biology at NYU Dentistry.

HIV latency—in which the virus lies dormant in T cells—presents a troublesome barrier to developing treatments that eliminate HIV from the body. It is largely the result of repressive epigenetic changes to the HIV-associated chromatin, the substance within a chromosome consisting of DNA and protein. Understanding the epigenetic changes that result in productive infection versus latency would provide an important clue for developing a curative treatment.

“The search for treatments which might cure HIV infection or permanently repress the virus depend upon a thorough understanding of these processes,” said Levy. “Our research seeks to develop new knowledge on of the regulation of HIV-1 chromatin, the installation of nucleosomes, and their histone post translational modifications.”

The NIH-funded project will describe both the initial steps in HIV chromatization and the long-term processes that lead to reversible latency and irreversible repression. The researchers are investigating the earliest events in the establishment of HIV-1 chromatin organization, which they have determined occurs soon after reverse transcription and is influenced by both cellular and viral factors.

The research will also explore the influence of the viral protein Vpr on these processes. Previous research by Levy found that HIV-1 Vpr can reactivate latent HIV, and his new work demonstrates that Vpr influences the structure of HIV-1 chromatin that drives the switch between active replication and latency.

By defining the epigenetic landscape of newly generated HIV-1 genomes and latent proviruses, and the contribution of Vpr to this process, the researchers anticipate gaining useful insights into HIV infection and latency.

“These studies will provide vital information and perhaps new targets for the development of therapeutics that can purge HIV from the body or permanently repress virus replication without continual antiviral treatments,” said Levy.

"The recent announcement that a second person has been cured of HIV infection brings renewed optimism that a cure can be found that is more generally applicable. The two individuals who have been cured were also treated for cancer with bone marrow transplants, something that is not going to be useful to the HIV infected population at large. Nevertheless, achievements such as these provide vital clues about how to develop broadly useful methods for HIV clearance," Levy added.

About NYU College of Dentistry

Founded in 1865, New York University College of Dentistry (NYU Dentistry) is the third oldest and the largest dental school in the US, educating 9 percent of the nation’s dentists. NYU Dentistry has a significant global reach with a highly diverse student body. Visit https://dental.nyu.edu for more.

Zest Dental Solutions, the only manufacturer of the LOCATOR® Family of Attachment Systems and provider of clinician trusted dental materials and small equipment, announces their second quarter roster of Continuing Education (CE) Courses. 

Zest’s mission is to enhance the knowledge and skills of the clinician through unique education opportunities helping them provide the highest quality treatment to their patients. Classes are led by nationally recognized and accredited industry leaders at the Zest Corporate Headquarters in Carlsbad, CA and at other locations throughout the country. Attendees will receive applicable CE Hours upon completion of each course. 

Courses for the second quarter of 2019 include:

To view a complete list of dates and course information or to register for an upcoming course, visit zestdent.com/index.php/education or call 800-262-2310, ext. 344.